Regulation of Adverse Event Reporting in Biotechnology Trials in China

1. Introduction

Adverse event reporting is a fundamental component of clinical trial regulation in China. It aims to protect trial participants, ensure the reliability of clinical research, and enable regulatory authorities to identify previously unknown risks associated with biotechnology products, including gene therapies, cell therapies, vaccines, biologics, and genetically engineered medicinal products.

China's regulatory framework places responsibilities on sponsors, clinical trial institutions, investigators, ethics committees, and the National Medical Products Administration (NMPA). The central principle is that participant safety takes priority over the commercial or scientific objectives of a clinical trial.

Adverse event reporting is particularly important in biotechnology trials because biological products may produce unexpected immune responses, delayed toxicities, serious infections, or long-term complications. Consequently, safety monitoring must continue throughout the trial and, where required, after its completion.

2. Principal Legal and Regulatory Framework

China regulates adverse event reporting through several interconnected legal instruments.

A. Drug Administration Law of the People's Republic of China

The Drug Administration Law, revised in 2019, establishes the general legal framework for drug research, clinical trials, marketing authorisation, and post-market safety supervision.

It requires drug-development activities to comply with applicable legal and technical standards. Sponsors and marketing authorisation holders must fulfil their respective safety responsibilities, while the NMPA and its subordinate regulatory authorities exercise supervisory powers.

For biotechnology trials, this framework provides the overarching legal basis for investigating drug-related risks, supervising clinical research, and taking regulatory action when safety concerns arise.

B. Provisions for Drug Registration

The Provisions for Drug Registration, issued by the NMPA in 2020, regulate the authorisation and supervision of clinical trials in China.

They establish requirements concerning clinical trial applications, trial conduct, safety evaluation, and regulatory intervention. Where significant safety concerns arise, the regulatory authority may require corrective action, suspend relevant activities, or take other measures permitted by law.

These provisions are especially relevant when adverse events suggest that a biological product's existing risk profile is incomplete or that the trial's benefit-risk balance has changed.

C. Good Clinical Practice (GCP), 2020

China's revised Good Clinical Practice requirements, jointly issued by the NMPA and the National Health Commission and effective from 1 July 2020, are central to adverse event reporting.

GCP distinguishes between an adverse event (AE) and a serious adverse event (SAE).

Adverse event: Any unfavourable medical occurrence in a clinical trial participant who has received a medicinal product, whether or not it is considered related to that product.

Serious adverse event: An event that results in death, is life-threatening, requires inpatient hospitalisation or prolongs existing hospitalisation, results in persistent or significant disability, causes a congenital anomaly, or constitutes another medically important event requiring intervention to prevent such outcomes.

The distinction matters because every adverse event must be appropriately documented and assessed, whereas serious events trigger additional notification, investigation, and reporting duties.

3. Reporting Obligations and Timelines

A. Duties of the Investigator

Under Article 26 of the 2020 GCP, investigators must immediately report serious adverse events in writing to the sponsor, except where the protocol or other applicable documents specify that certain events do not require immediate reporting. Investigators must also provide detailed written follow-up reports.

The investigator should:

Provide appropriate medical treatment to the affected participant.

Record the event accurately in the source documents and clinical trial records.

Report serious adverse events promptly and submit subsequent medical information.

Supply relevant documentation in fatal cases, including autopsy or final medical reports where required.

Inform the ethics committee about suspected unexpected serious adverse reactions (SUSARs) communicated by the sponsor.

B. Duties of the Sponsor

Article 48 of the 2020 GCP requires sponsors to evaluate safety information received from any source, considering seriousness, causality, and whether the reaction was expected.

Sponsors must rapidly report SUSARs to participating investigators, clinical trial institutions, and ethics committees, and report them to the relevant drug regulatory and health authorities.

The sponsor must also prepare annual Development Safety Update Reports (DSURs). Under the 2020 Provisions for Drug Registration, the DSUR is generally submitted within two months after each full year following clinical trial approval.

The precise reporting deadline for individual SUSARs depends on the applicable reporting requirements and event classification. It should not be assumed that every adverse event has the same statutory deadline.

4. Special Considerations for Biotechnology Products

Biotechnology trials require particular attention to delayed and unpredictable risks.

Gene therapy: Investigators may need extended monitoring for delayed toxicities, immune reactions, or genetic complications.

Cell therapy: Cytokine release syndrome, neurotoxicity, infections, and unexpected immune responses may require urgent assessment.

Biological medicines and vaccines: Investigators must assess serious hypersensitivity reactions, immune-mediated disorders, and unexpected systemic effects.

Sponsors should incorporate product-specific risks into the protocol, investigator's brochure, informed consent documentation, and safety monitoring procedures.

5. Case Law and Regulatory Practice

Chinese adverse-event reporting requirements are principally enforced through administrative regulation and clinical trial supervision. Publicly identifiable judicial decisions specifically addressing failure to report SUSARs in biotechnology trials are limited; therefore, the following examples distinguish documented regulatory requirements from judicial precedents.

A. Regulatory precedent: 2020 Drug Registration Provisions

Articles 30–31 of the Provisions for Drug Registration establish that serious safety risks may require protocol modification, suspension, or termination of a clinical trial. Extensive unexpected serious adverse reactions or evidence of serious investigational-drug quality problems may require immediate termination by the sponsor and trial institution.

Legal significance: These provisions demonstrate that failure to manage serious safety risks can have consequences beyond reporting deficiencies, including interruption of the entire clinical development programme.

B. Practical evidence: SUSAR Reporting Study (2022)

A study published in Adverse Drug Reactions Journal examined SUSAR reporting requirements at 194 Chinese clinical trial sites. It identified substantial variation in reporting timelines and procedures, with some sites lacking explicit requirements or consistent ethics committee processes.

Legal significance: Although this study is not a court judgment, it demonstrates practical compliance challenges under the revised GCP and supports the need for standardised reporting procedures, training, and institutional oversight.

C. Drug Administration Law: Enforcement framework

The Drug Administration Law supplies the broader legal basis for regulatory supervision and penalties for violations of drug-development requirements. Depending on the conduct and applicable provisions, violations may expose responsible organisations or individuals to administrative consequences.

However, a specific penalty cannot automatically be attributed to an adverse-event reporting failure without establishing the applicable statutory provision and the facts of the case.

6. Conclusion

China's adverse-event reporting framework combines the Drug Administration Law, Drug Registration Provisions, and 2020 GCP. Investigators must identify and report serious events promptly, while sponsors must assess safety signals, communicate SUSARs, prepare periodic safety updates, and implement risk-control measures.

For biotechnology trials, compliance requires more than submitting forms: it demands continuous risk assessment, accurate records, effective communication with ethics committees, and prompt regulatory intervention when participant safety is threatened.